共 50 条
Combination therapy with the type II anti-CD20 antibody obinutuzumab
被引:7
|作者:
Klein, Christian
[1
]
Bacac, Marina
[1
]
Umana, Pablo
[1
]
Fingerle-Rowson, Gunter
[2
]
机构:
[1] Roche Innovat Ctr Zurich, Roche Pharmaceut Res & Early Dev, Zurich, Switzerland
[2] F Hoffmann Roche Ltd, Pharma Dev Clin Oncol, Basel, Switzerland
关键词:
B-cell lymphoma;
CD20;
chronic lymphocytic leukemia;
non-Hodgkin lymphoma;
obinutuzumab;
targeted therapy;
CHRONIC LYMPHOCYTIC-LEUKEMIA;
NON-HODGKIN-LYMPHOMA;
RITUXIMAB-REFRACTORY INDOLENT;
BRUTONS TYROSINE KINASE;
B-CELL MALIGNANCIES;
FOLLICULAR LYMPHOMA;
PLUS RITUXIMAB;
MONOCLONAL-ANTIBODIES;
ANTITUMOR-ACTIVITY;
BTK INHIBITOR;
D O I:
10.1080/13543784.2017.1373087
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Introduction: Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody approved for first-line treatment of chronic lymphocytic leukemia (CLL) in combination with chlorambucil and for treatment of rituximab-refractory follicular lymphoma (FL). Areas covered: We describe current preclinical and clinical evidence supporting the combination of obinutuzumab with not only chemotherapy but also novel targeted therapies for B-cell hematologic malignancies, and its application in chemoimmunotherapy. We also provide an overview of the current clinical trial landscape investigating novel combination therapies based on obinutuzumab. Expert opinion: Within the next 10 years the treatment of B-cell malignancies with obinutuzumab is expected to increasingly move towards chemotherapy-free regimens. Novel combinations of obinutuzumab will be explored with targeted therapies, antibody-drug conjugates, and/or other immunotherapeutic agents, with the aim to achieve clinically meaningful improvements in efficacy and patient safety.
引用
收藏
页码:1145 / 1162
页数:18
相关论文